Entrada Therapeutics, Inc. (TRDA)
NASDAQ: TRDA · Real-Time Price · USD
6.85
-9.18 (-57.27%)
At close: May 7, 2026, 4:00 PM EDT
6.84
-0.01 (-0.15%)
After-hours: May 7, 2026, 7:59 PM EDT
Entrada Therapeutics Stock Forecast
Stock Price Forecast
The 3 analysts that cover Entrada Therapeutics stock have a consensus rating of "Strong Buy" and an average price target of $21, which forecasts a 206.57% increase in the stock price over the next year. The lowest target is $20 and the highest is $23.
Price Target: $21 (+206.57%)
Analyst Consensus: Strong Buy
* Price targets were last updated on Apr 6, 2026.
Analyst Ratings
The average analyst rating for Entrada Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 | May '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Buy | 1 | 1 | 0 | 0 | 1 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 3 | 3 | 2 | 2 | 3 | 3 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Oppenheimer | Oppenheimer | Buy Maintains $21 → $23 | Buy | Maintains | $21 → $23 | +235.77% | Apr 6, 2026 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $20 | Strong Buy | Reiterates | $20 | +191.97% | Feb 18, 2026 |
| Guggenheim | Guggenheim | Strong Buy Initiates $20 | Strong Buy | Initiates | $20 | +191.97% | Feb 11, 2026 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $20 | Strong Buy | Reiterates | $20 | +191.97% | May 20, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $20 | Strong Buy | Reiterates | $20 | +191.97% | Mar 31, 2025 |
Financial Forecast
Revenue This Year
29.65M
from 25.42M
Increased by 16.64%
Revenue Next Year
52.11M
from 29.65M
Increased by 75.73%
EPS This Year
-4.06
from -3.47
EPS Next Year
-3.68
from -4.06
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 63.0M | 89.3M | ||||||
| Avg | 29.7M | 52.1M | ||||||
| Low | n/a | 24.9M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 147.8% | 201.0% | ||||||
| Avg | 16.6% | 75.7% | ||||||
| Low | - | -16.0% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | -2.60 | -2.03 | ||||||
| Avg | -4.06 | -3.68 | ||||||
| Low | -4.56 | -4.97 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | - | ||||||
| Avg | - | - | ||||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data sources.